NP-R@M-M |
|
Vaxjo ID |
290 |
|
Vaccine Adjuvant Name |
NP-R@M-M |
|
Adjuvant VO ID |
VO_0005664
|
|
Description |
A nanovaccine combining PLGA nanoparticles (loaded with R837), cancer cell membranes (as tumor antigens), and mannose (for dendritic cell targeting) |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Those adjuvant nanoparticles (NP-R) are then coated with cancer cell membranes (NP-R@M), whose surface proteins could act as tumor-specific antigens. |
|
Structure |
"Core-shell nanoparticles: Core: PLGA + R837 Shell: Cancer cell membrane Surface: DSPE-PEG-Mannose " |
|
Appearance |
Milky colloidal suspension of nanoparticles (~160 nm diameter) |
|
Storage |
Stored in PBS, likely at 4 °C; exact long-term storage conditions not detailed. |
|
Preparation |
"PLGA nanoprecipitation R837 loading Membrane coating via incubation Mannose insertion with DSPE-PEG-Man" |
|
Dosage |
In mice: 200 μL per injection (10 mg/mL PLGA, 0.1 mg/mL R837) |
|
Function |
With great efficacy to delay tumor development as a prevention vaccine, vaccination with such NP-R@M-M in combination with checkpoint-blockade therapy further demonstrates outstanding therapeutic efficacy to treat established tumors. Therefore, our work presents an innovative way to fabricate cancer nanovaccines, which in principle may be applied for a wide range of tumor types. |
|
Safety |
"Shown to be safe in vitro and in vivo in mice Minimal toxicity toward dendritic cells" |
| References |
Yang et al., 2018: Yang R, Xu J, Xu L, Sun X, Chen Q, Zhao Y, Peng R, Liu Z. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. ACS nano. 2018; 12(6); 5121-5129. [PubMed: 29771487].
|
